Adenosine vs Diltiazem for Treatment of SVT in the ED

Phase 4RecruitingNCT06993038

Anne E. Zepeski20 enrolled

Overview

This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Supraventricular Tachycardia (SVT)

Interventions

adenosineDRUG

IV adenosine at standard doses for SVT (6 mg, 12 mg)

diltiazemDRUG

IV diltiazem at standard doses for SVT (0.25 mg/kg)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Adult patients (18 years and older) 2. Diagnosis of acute, stable SVT in the emergency department Exclusion Criteria: 1. Receipt of IV AV-nodal blocking agents prior to study enrollment (includes adenosine, non-dihydropyridine calcium channel blockers, beta-antagonists in pre-hospital and/or hospital setting). 2. Reported or confirmed personal history of Wolff-Parkinson-White (WPW) syndrome 3. History of heart failure with reduce ejection fraction (HFrEF) (LVEF\</= 40%) 4. Severe bronchoconstrictive lung disease 5. Prior hypersensitivity to study medication 6. Previously enrolled in pilot study 7. Pregnant 8. Incarcerated

Locations (1)

University of Iowa Health Care

Iowa City, Iowa, United States

RECRUITING

Outcomes

Primary Outcomes

Feasibility outcome

Patients with stable SVT are identified in the ED (Threshold \>90%)

Time frame: From enrollment to the end of ED encounter (up to 24 hours).

Feasibility outcome

Eligible participants who provide consent to participate (Threshold \>50%)

Time frame: From enrollment to the end of ED encounter (up to 24 hours).

Feasibility outcome

Participants who complete all study procedures (Threshold \>80%)

Time frame: From enrollment to the end of ED encounter (up to 24 hours).

Central Contacts

Anne Zepeski, PharmD

CONTACT

(319) 356-2577 anne-zepeski@uiowa.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.